NOTES TO CONSOLIDATED CONDENSED FINANCIAL STATEMENTS
(UNAUDITED)
1. Description of Business
Cleveland BioLabs, Inc. ("
CBLI
" or the "
Company
") is an innovative biopharmaceutical company developing novel approaches to activate the immune system and address serious medical needs. Our proprietary platform of Toll-like immune receptor activators has applications in radiation mitigation and immuno-oncology. We combine our proven scientific expertise and our depth of knowledge about our products’ mechanisms of action into a passion for developing drugs to save lives. Our most advanced product candidate is entolimod, an immune-stimulatory agent, which we are developing as a radiation countermeasure and an immunotherapy for oncology and other indications.
CBLI was incorporated in Delaware in June 2003 and is headquartered in Buffalo, New York. CBLI conducts business in the United States ("
U.S.
") and in the Russian Federation ("
Russia
"), through several subsidiaries including:
one
wholly-owned subsidiary, BioLab 612, LLC ("
BioLab 612
"), which began operations in 2012; Panacela Labs, Inc. ("
Panacela
"), which was formed by us and Joint Stock Company “RUSNANO” ("
RUSNANO
") our financial partner in the venture, in 2011; and, Incuron LLC ("
Incuron
"), which was formed by us and Bioprocess Capital Ventures ("
BCV
") our financial partner in the venture, in 2010. During the twenty-one months ended
September 30, 2016
our ownership in Incuron has decreased from being a minority shareholder at January 1, 2015 to no longer being a shareholder as of April 29, 2015. Unless otherwise noted, references to the “Company,” “we,” “us” and “our” refer to Cleveland BioLabs, Inc. together with its subsidiaries.
2. Summary of Significant Accounting Policies
Basis of Presentation and Consolidation
The accompanying unaudited consolidated condensed financial statements include the accounts of CBLI, BioLab 612, and Panacela. The accounts of Incuron are presented using the equity method of accounting for the period from January 1, 2015 through April 29, 2015, the date that we completed a sale of our entire equity interest in Incuron. All significant intercompany balances and transactions have been eliminated in consolidation.
The consolidated condensed balance sheet as of
December 31, 2015
, which has been derived from audited financial statements, and the unaudited interim consolidated condensed financial statements have been prepared in accordance with accounting principles generally accepted in the United States ("
GAAP
") for interim consolidated financial information and in accordance with the instructions to Form 10-Q and Article 8 of Regulation S-X of the Securities and Exchange Commission ("
SEC
"). Certain information and footnote disclosures normally included in consolidated financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to such rules and regulations. These consolidated condensed financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto contained in the Company’s Annual Report on Form 10-K for the year ended
December 31, 2015
, as filed with the SEC (the "2015 Form 10-K").
In the opinion of the Company’s management, any adjustments contained in the accompanying unaudited consolidated financial statements are of a normal recurring nature, and are necessary to fairly present the financial position of the Company as of
September 30, 2016
, along with its results of operations for the three and
nine
month periods ended
September 30, 2016
and
2015
and cash flows for the
nine
month periods ended
September 30, 2016
and
2015
. Interim results are not necessarily indicative of results that may be expected for any other interim period or for an entire year.
On January 28, 2015, the Company, after receiving approval from the Company’s stockholders and board of directors, executed a reverse stock split of the Company’s common stock at the ratio of
1:20
. Unless otherwise indicated, all of the Company’s historical share balances and share price-related data have been adjusted, on a retroactive basis, to reflect this ratio.
At
September 30, 2016
, we had cash, cash equivalents and short-term investments of
$14.9 million
in the aggregate. Management believes this capital will fund the Company's operations and cash requirements beyond one year.
Recent Accounting Pronouncements
In March 2016, the Financial Accounting Standards Board (“
FASB
”) issued a new standard that changes the accounting for certain aspects of share-based payments to employees. The new guidance requires excess tax benefits and tax deficiencies to be recorded in the income statement when the awards vest or are settled. In addition, cash flows related to excess tax benefits will no longer
be separately classified as a financing activity apart from other income tax cash flows. The standard also allows us to repurchase more of an employee’s shares for tax withholding purposes without triggering liability accounting, clarifies that all cash payments made on an employee’s behalf for withheld shares should be presented as a financing activity on our cash flows statement, and provides an accounting policy election to account for forfeitures as they occur. The new standard is effective for us beginning January 1, 2017, with early adoption permitted. This new standard is not expected to have a significant impact on the Company’s financial statements.
In February 2016, the FASB issued a new standard related to leases to increase transparency and comparability among organizations by requiring the recognition of lease assets and lease liabilities on the balance sheet. Most prominent among the amendments is the recognition of assets and liabilities by lessees for those leases classified as operating leases under previous U.S. GAAP. Under the new standard, disclosures are required to meet the objective of enabling users of financial statements to assess the amount, timing, and uncertainty of cash flows arising from leases. The new standard will be effective for us beginning January 1, 2019, with early adoption permitted. We are currently evaluating the impact of this statement.
Use of Estimates
The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.
Short-Term Investments
The Company’s short-term investments are classified as available for sale. Accordingly, these investments are carried at fair market value. Short-term investments consisted of United States Treasury securities in the amount of
$9.9 million
which were owned by CBLI and had maturities of less than
12 months
. In addition,
$1.0 million
in certificates of deposit with maturity dates beyond three months and less than one year, and owned by Panacela, are also included. Unrealized gains and losses on available for-sale investments are reported as Other Comprehensive Loss, a separate component of stockholders’ equity. Realized gains and losses, and interest and dividends on available-for-sale securities are recorded in our Consolidated Statement of Operations as Interest and Other Expense. The cost of securities sold is based on the specific identification method.
Significant Customers and Accounts Receivable
The following table presents our revenue by customer, on a proportional basis, for the
three and nine
months ended
September 30, 2016
and
2015
.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended
September 30,
|
|
|
|
Nine Months Ended
September 30,
|
|
|
Customer
|
2016
|
|
2015
|
|
Variance
|
|
2016
|
|
2015
|
|
Variance
|
Department of Defense
|
43.8
|
%
|
|
6.4
|
%
|
|
37.4
|
%
|
|
35.8
|
%
|
|
2.2
|
%
|
|
33.6
|
%
|
Russian Government Agencies
|
40.0
|
%
|
|
52.6
|
%
|
|
(12.6
|
)%
|
|
43.3
|
%
|
|
56.3
|
%
|
|
(13.0
|
)%
|
Incuron, LLC
|
16.2
|
%
|
|
41.0
|
%
|
|
(24.8
|
)%
|
|
20.9
|
%
|
|
41.5
|
%
|
|
(20.6
|
)%
|
Total
|
100.0
|
%
|
|
100.0
|
%
|
|
—
|
%
|
|
100.0
|
%
|
|
100.0
|
%
|
|
—
|
%
|
Our current Department of Defense ("
DoD
") revenues come from development contracts that expire in 2017 and 2018, although each contract may be extended. Our current Russian Government Agencies revenues come from development contracts that expire in 2016. Our Incuron, LLC revenues come from a service agreement that is renegotiated annually
Accounts receivable consist of amounts due under reimbursement contracts with these customers. The Company extends unsecured credit to customers under normal trade agreements, which generally require payment within
30 days
.
Restricted Cash
Restricted cash includes certificates of deposit, denominated in Russian rubles, which collateralize Panacela and BioLab 612 contracts with the Ministry of Industry and Trade of the Russian Federation. These deposits provide additional assurance that
Panacela and BioLab 612 will satisfactorily perform their statements of work under the contracts. Both Panacela and BioLab 612 anticipate receiving these deposits at the completion of the contracts.
We previously disclosed that the Bank of Russia appointed temporary management of NOTA-Bank and that we had written off the full value of our restricted cash deposits with NOTA-Bank, as of the year ended December 31, 2015. The remaining amount of "Restricted Cash" at
September 30, 2016
, is on deposit with other banking institutions. During 2016 we adjusted the estimated loss on our restricted cash as more facts have become known which has resulted in a net gain of
$40,517
, which was recorded as Gain (loss) on Investments in the Statement of Operations for the
nine months ended September 30, 2016
.
Other Comprehensive Income (loss)
The Company applies the Codification on comprehensive income (loss) that requires disclosure of all components of comprehensive income (loss) on an annual and interim basis. Comprehensive income (loss) is defined as the change in equity of a business enterprise during a period from transactions and other events and circumstances from non-owner sources. The following table presents the changes in accumulated other comprehensive loss for the
nine months ended
September 30, 2016
.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Unrealized loss on available-for-sale securities
|
|
Gains and losses on foreign exchange translations
|
|
Total
|
Beginning balance
|
$
|
(6,190
|
)
|
|
$
|
(401,861
|
)
|
|
$
|
(408,051
|
)
|
Other comprehensive income/(loss) before reclassifications
|
7,706
|
|
|
58,188
|
|
|
65,894
|
|
Amounts reclassified from accumulated other comprehensive loss
|
—
|
|
|
(65,429
|
)
|
|
(65,429
|
)
|
Ending balance
|
$
|
1,516
|
|
|
$
|
(409,102
|
)
|
|
$
|
(407,586
|
)
|
Accounting for Stock-Based Compensation
The 2006 Equity Incentive Plan, as amended, or the Plan, authorizes CBLI to grant (i) options to purchase common stock, (ii) restricted or unrestricted stock units, and (iii) stock appreciation rights, so long as the exercise or grant price of each are at least equal to the fair market value of the stock on the date of grant. As of
September 30, 2016
, an aggregate of
650,000
shares of common stock were authorized for issuance under the Plan, of which a total of
285,332
shares of common stock remained available for future awards and
236,124
shares of common stock have been reserved for issuance upon exercise of currently outstanding stock options. A single participant cannot be awarded more than
100,000
shares annually. Awards granted under the Plan have a contractual life of no more than
10 years
. The terms and conditions of equity awards (such as price, vesting schedule, term and number of shares) under the Plan are specified in an award document, and approved by the Company’s board of directors or its management delegates.
The 2013 Employee Stock Purchase Plan, or ESPP, provides a means by which eligible employees of the Company and certain designated related corporations may be given an opportunity to purchase shares of common stock. As of
September 30, 2016
, there are
325,000
shares of common stock reserved for purchase under the ESPP. The number of shares reserved for purchase under the ESPP increases on January 1 of each calendar year by the lesser of: (i)
10%
of the total number of shares of common stock outstanding on December 31st of the preceding year, or (ii)
100,000
shares of common stock. The ESPP allows employees to use up to
15%
of their compensation to purchase shares of common stock at an amount equal to
85%
of the fair market value of the Company’s common stock on the offering date or the purchase date, whichever is less.
The Company utilizes the Black-Scholes valuation model for estimating the fair value of all stock options granted where the vesting period is based on length of service or performance, while a Monte Carlo simulation model is used for estimating the fair value of stock options with market-based vesting conditions. Set forth below are the assumptions used in valuing the stock options granted during the
nine months ended
September 30, 2015
and a discussion of the Company’s methodology for developing each of the assumptions used.
No
options were granted during the
nine months ended
September 30, 2016
.
|
|
|
|
|
2015
|
Risk-free interest rate
|
1.35 - 1.59%
|
|
Expected dividend yield
|
0.0
|
%
|
Expected life
|
5 - 5.5 years
|
|
Expected volatility
|
76.66 - 116.10%
|
|
“Risk-free interest rate” means the range of U.S. Treasury rates with a term that most closely resembles the expected life of the option as of the date the option is granted.
“Expected dividend yield” means the Company does not pay regular dividends on its common stock and does not anticipate paying any dividends in the foreseeable future.
“Expected life” means the period of time that options granted are expected to remain outstanding, based wholly on the use of the simplified (safe harbor) method. The simplified method is used because the Company does not yet have adequate historical exercise information to estimate the expected life the options granted.
“Expected volatility” means a measure of the amount by which a financial variable, such as share price, has fluctuated (historical volatility) or is expected to fluctuate (implied volatility) during a period. Expected volatility is based on the Company’s historical volatility and incorporates the volatility of the common stock of comparable companies when the expected life of the option exceeds the Company’s trading history.
Income Taxes
No
income tax expense was recorded for the
three and nine
months ended
September 30, 2016
and
2015
, as the Company does not expect to have taxable income for
2016
and did not have taxable income in
2015
. A full valuation allowance has been recorded against the Company’s deferred tax asset.
Additionally, as disclosed in Note 9, Income Taxes, to the Company’s consolidated financial statements included in the 2015 Form 10-K, the Company had U.S. federal net operating loss carryforwards of approximately
$128,665,000
, which begin to expire if not utilized by 2023, and approximately
$3,750,000
of federal tax credit carryforwards which begin to expire if not utilized by 2024. The Company also has U.S. state net operating loss carryforwards of approximately
$118,097,000
, which begin to expire if not utilized by 2027 and state tax credit carryforwards of approximately
$336,000
, which begin to expire if not utilized by 2022. The purchase of
6,459,948
shares of common stock by Mr. Davidovich on July 9, 2015 resulted in Mr. Davidovich owning
60.2%
of the Company. We therefore believe it highly likely that this transaction, more fully described in Note 6 Stockholders’ Equity, to the Company's consolidated financial statements included in the 2015 Form 10-K will be viewed by the U.S. Internal Revenue Service as a change of ownership as defined by Section 382 of the Internal Revenue Code, or Section 382. Consequently, the utilization of these net operating loss and tax credit carryforwards, as well as any additional net operating loss and tax credit carryforwards generated in 2015 through the issuance date, will be limited according to the provisions of Section 382, which will significantly limit the Company’s ability to use these carryforwards to offset taxable income on an annual basis in future periods. As such, a significant portion of these carryforwards will likely expire before they can be utilized, even if the Company is able to generate taxable income that, except for this transaction, would have been sufficient to fully utilize these carryforwards.
Earnings (Loss) per Share
Basic net loss per share of common stock excludes dilution for potential common stock issuances and is computed by dividing net loss by the weighted average number of shares outstanding for the period. Diluted net loss per share reflects the potential dilution that could occur if securities or other contracts to issue common stock were exercised or converted into common stock. Diluted net loss per share is identical to basic net loss per share as potentially dilutive securities have been excluded from the calculation of diluted net loss per common share because the inclusion of such securities would be antidilutive.
The Company has excluded the following securities from the calculation of diluted net loss per share because all such securities were antidilutive for the periods presented. Additionally, there were no dilutive securities outstanding as of September 30, 2016.
|
|
|
|
|
|
|
|
As of September 30,
|
Common Equivalent Securities
|
2016
|
|
2015
|
Warrants
|
2,148,741
|
|
|
2,272,523
|
|
Options
|
236,124
|
|
|
365,784
|
|
Total
|
2,384,865
|
|
|
2,638,307
|
|
Contingencies
From time to time, the Company may have certain contingent liabilities that arise in the ordinary course of business. The Company accrues for liabilities when it is probable that future expenditures will be made and such expenditures can be reasonably estimated. For all periods presented, the Company was not a party to any pending material litigation that was estimable and had a probability of loss.
3. Fair Value of Financial Instruments
The Company measures and records warrant liabilities at fair value in the accompanying financial statements. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability, an exit price, in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. The three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value, includes:
|
|
•
|
Level 1 – Observable inputs for identical assets or liabilities such as quoted prices in active markets;
|
|
|
•
|
Level 2 – Inputs other than quoted prices in active markets that are either directly or indirectly observable; and
|
|
|
•
|
Level 3 – Unobservable inputs in which little or no market data exists, which are therefore developed by the Company using estimates and assumptions that reflect those that a market participant would use.
|
Cash equivalents include United States Treasury Notes with original maturities of three months or less, at time of purchase and money market funds. Short-term investments primarily include United States Treasury Notes, along with certificates of deposit at commercial banking institutions, both with maturities of three months or more at time of purchase.
The valuation methodologies used to measure the fair value of the company’s assets and instruments classified in stockholders’ equity are described as follows: United States Treasury Notes and money market funds included in cash equivalents and short-term investments are valued at the closing price reported by an actively traded exchange and are included as Level 1 measurements in the table below. Certificates of deposit are carried at amortized cost, which approximates fair value and are included within short-term investments as a Level 2 measurement in the table below.
The following tables represent the Company’s fair value hierarchy for its financial assets and liabilities measured at fair value on a recurring basis.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
As of September 30, 2016
|
|
Level 1
|
|
Level 2
|
|
Level 3
|
|
Total
|
Assets:
|
|
|
|
|
|
|
|
Cash and cash equivalents
|
$
|
421,399
|
|
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
421,399
|
|
Short-term investments
|
9,896,428
|
|
|
980,713
|
|
|
—
|
|
|
10,877,141
|
|
Total assets
|
$
|
10,317,827
|
|
|
$
|
980,713
|
|
|
$
|
—
|
|
|
$
|
11,298,540
|
|
Liabilities:
|
|
|
|
|
|
|
|
Accrued warrant liability
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
1,348,845
|
|
|
$
|
1,348,845
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
As of December 31, 2015
|
|
Level 1
|
|
Level 2
|
|
Level 3
|
|
Total
|
Assets:
|
|
|
|
|
|
|
|
Cash and cash equivalents
|
$
|
1,885,826
|
|
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
1,885,826
|
|
Short-term investments
|
13,701,273
|
|
|
—
|
|
|
—
|
|
|
13,701,273
|
|
Total assets
|
$
|
15,587,099
|
|
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
15,587,099
|
|
Liabilities:
|
|
|
|
|
|
|
|
Accrued warrant liability
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
4,048,900
|
|
|
$
|
4,048,900
|
|
The Company uses the Black-Scholes model to measure the accrued warrant liability and its accrual for compensatory stock options not yet issued. The following are the assumptions used to measure the accrued warrant liability which were determined in a manner consistent with that described for grants of options to purchase common stock as set forth in Note 2:
|
|
|
|
|
|
|
|
|
|
September 30, 2016
|
|
December 31, 2015
|
Stock Price
|
$
|
1.65
|
|
|
$
|
3.49
|
|
Exercise Price
|
$3.00 - $60.00
|
|
|
$3.00 - $100.00
|
|
Term in years
|
0.42 – 4.85
|
|
|
0.48 - 5.60
|
|
Volatility
|
60.48% - 99.78%
|
|
|
64.00% - 114.74%
|
|
Annual rate of quarterly dividends
|
—
|
%
|
|
—
|
%
|
Discount rate- bond equivalent yield
|
.25% - 1.12%
|
|
|
.31% - 1.86%
|
|
The following table sets forth a summary of changes in the fair value of the Company’s Level 3 fair value measurements for the periods indicated:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended
September 30, 2016
|
|
Three Months Ended September 30, 2015
|
|
Accrued
Warrant
Liability
|
|
Accrued
Warrant
Liability
|
|
Compensatory
Stock Options
Issued After
Year End
|
Beginning Balance
|
$
|
3,183,350
|
|
|
$
|
5,356,391
|
|
|
$
|
132,295
|
|
Total (gains) or losses, realized and unrealized, included in earnings (1)
|
(1,834,505
|
)
|
|
(46,717
|
)
|
|
(26,381
|
)
|
Issuances
|
—
|
|
|
—
|
|
|
—
|
|
Settlements
|
—
|
|
|
—
|
|
|
(105,914
|
)
|
Ending Balance
|
$
|
1,348,845
|
|
|
$
|
5,309,674
|
|
|
$
|
—
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Nine Months Ended
September 30, 2016
|
|
Nine Months Ended
September 30, 2015
|
|
Accrued
Warrant
Liability
|
|
Accrued
Warrant
Liability
|
|
Compensatory
Stock Options
Issued After
Year End
|
Beginning Balance
|
$
|
4,048,900
|
|
|
$
|
862,074
|
|
|
$
|
132,295
|
|
Total (gains) or losses, realized and unrealized, included in earnings (1)
|
(2,700,055
|
)
|
|
1,482,689
|
|
|
(26,381
|
)
|
Issuances
|
—
|
|
|
3,636,260
|
|
|
—
|
|
Settlements
|
—
|
|
|
(671,349
|
)
|
|
(105,914
|
)
|
Ending Balance
|
$
|
1,348,845
|
|
|
$
|
5,309,674
|
|
|
$
|
—
|
|
|
|
(1)
|
Unrealized gains or losses related to the accrued warrant liability were included as change in value of accrued warrant liability. There were
no
realized gains or losses for the
three and nine
months ended
September 30, 2016
and
2015
.
|
As of
September 30, 2016
and
December 31, 2015
, the Company had
no
assets or liabilities that were measured at fair value on a nonrecurring basis.
The Company considers the accrued warrant liability and compensatory stock options not yet issued to be Level 3 because some of the inputs into the measurements are neither directly or indirectly observable. Both the accrued warrant liability and compensatory stock options not yet issued use management’s estimate for the expected term. Additionally, the number of compensatory options awarded involves an estimate of management’s performance in relation to the targets set forth in the Company’s Executive Compensation Plan. As of
September 30, 2016
, the Black-Scholes pricing model was used as the valuation technique for the accrued warrant liability and used the unobservable input for the expected term of
0.42 – 4.85
years.
Management believes the value of the accrued warrant liability is more sensitive to a change in the Company’s stock price at the end of the respective reporting period as opposed to a change in the unobservable input described above.
The carrying amounts of the Company’s short-term financial instruments, which include cash and cash equivalents, accounts receivable and accounts payable, approximate their fair values due to their short maturities.
4. Sale of Incuron
On April 29, 2015, CBLI entered into an agreement to sell its equity stake in Incuron to Dr. Mikhail Mogutov, Chairman of Incuron’s Board of Directors and founder of BCV and/or his designee. The Company’s equity stake in Incuron was sold for (i)
$3 million
in cash and (ii) the transfer of
264,318
shares of the Company’s common stock to escrow. The escrow agent was instructed to sell the shares and to remit the net proceeds from the sale of those share to CBLI after deducting sales commissions and escrow agent fees. At the time of sale, CBLI had a recorded asset value of
$3,906,321
for its interest in Incuron. After recording the
$3 million
of cash proceeds from the sale,
$906,321
remained as a cost basis associated with the transfer of the
264,318
shares of the Company’s common stock to escrow and was recorded as treasury stock. As of December 31, 2015,
105,418
shares had been sold and
$417,545
in cash had been received from the escrow agent. As of
September 30, 2016
, the remaining shares have been sold and
$391,624
in cash has been received from the escrow agent. In addition, CBLI assigned its remaining intellectual property relating to Curaxin CBL0137 to Incuron in exchange for a
2%
royalty on the future commercialization, licensing or sale of the Curaxin CBL0137 technology.
5. Debt
On September 30, 2013, CBLI and BioLab 612 entered into a Loan and Security Agreement (the "
Loan Agreement
"), with Hercules Technology II, L.P. ("
Hercules
") pursuant to which we issued a
$6.0 million
note. In June 2014, CBLI repaid
$4.0 million
of the loan. Between June 2014 and August 2015, CBLI repaid the remaining principal and interest in accordance with the provisions of the Loan Agreement. In August 2015, CBLI fully paid the remaining obligations of the Loan Agreement along with a prepayment penalty of approximately
$28,000
and expensed approximately
$76,000
in deferred charges.
On September 3, 2013, Panacela entered into a Master Agreement and a Convertible Loan Agreement with RUSNANO, and CBLI pursuant to which Panacela issued a
$1,530,000
note payable to RUSNANO (the "
Panacela Loan
"). The Panacela Loan bore interest at a rate of
16.3%
per annum and matured on September 10, 2015. In December 2015, the Panacela Loan was fully retired.
6. Stockholders’ Equity
The Company has granted options to purchase shares of common stock. The following is a summary of option award activity during the
nine months ended September 30, 2016
:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total Stock
Options
Outstanding
|
|
Weighted
Average Exercise
Price per Share
|
|
Nonvested
Stock Options
|
|
Weighted
Average Grant
Date Fair Value
per Share
|
December 31, 2015
|
343,643
|
|
|
$
|
46.60
|
|
|
42,000
|
|
|
$
|
1.99
|
|
Granted
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
Vested
|
—
|
|
|
—
|
|
|
(42,000
|
)
|
|
1.99
|
|
Forfeited, Canceled
|
(107,519
|
)
|
|
55.59
|
|
|
—
|
|
|
—
|
|
September 30, 2016
|
236,124
|
|
|
$
|
42.50
|
|
|
—
|
|
|
$
|
—
|
|
The following is a summary of outstanding stock options as of
September 30, 2016
:
|
|
|
|
|
|
|
|
|
|
As of September 30, 2016
|
|
Stock Options
Outstanding
|
|
Vested Stock
Options
|
Quantity
|
236,124
|
|
|
236,124
|
|
Weighted-average exercise price
|
$
|
42.50
|
|
|
$
|
42.50
|
|
Weighted Average Remaining Contractual Term (in Years)
|
6.27
|
|
|
6.27
|
|
Intrinsic value
|
$
|
—
|
|
|
$
|
—
|
|
For the
nine months ended September 30, 2016
and
2015
, the Company granted
0
and
131,500
stock options, respectively, with a weighted-average grant date fair value of
$0.00
and
$2.59
, respectively. For the
nine months ended September 30, 2016
and
2015
, the total fair value of options vested was
$83,789
and
$492,849
, respectively.
As of
September 30, 2016
, there was
no
total compensation cost not yet recognized related to unvested stock options.
7. Warrants
In connection with sales of the Company’s common stock and the issuance of debt instruments, warrants were issued which presently have exercise prices ranging from
$3.00
to
$60.00
. The warrants expire between
one
and
six
years from the date of grant, and are subject to the terms applicable in each agreement. The following table summarizes the activity in our outstanding warrants since
December 31, 2015
:
|
|
|
|
|
|
|
|
|
Number of
Warrants
|
|
Weighted Average
Exercise Price
|
December 31, 2015
|
2,222,155
|
|
|
$
|
13.98
|
|
Granted
|
—
|
|
|
—
|
|
Exercised
|
—
|
|
|
—
|
|
Forfeited, Canceled
|
(73,414
|
)
|
|
100.00
|
|
September 30, 2016
|
2,148,741
|
|
|
$
|
11.04
|
|
8. Significant Alliances and Related Parties
Roswell Park Cancer Institute
The Company has entered into several agreements with Roswell Park Cancer Institute, or RPCI, including: various sponsored research agreements, an exclusive license agreement and clinical trial agreements for the conduct of the Phase 1 entolimod oncology study and the Phase 1 CBL137 intravenous administration study. Additionally, the Company’s Chief Scientific Officer, or CSO, Dr. Andrei Gudkov, is the Senior Vice President of Basic Research at RPCI. The Company incurred
$87,762
and
$131,965
and
$536,841
and
$626,291
in expense to RPCI related to research grants and agreements for the
three
and
nine months ended September 30, 2016
and
2015
, respectively. The Company had
$20,759
and
$418,797
included in accounts
payable owed to RPCI at
September 30, 2016
and
2015
, respectively. In addition, the Company had
$135,824
and
$316,232
in accrued expenses payable to RPCI at
September 30, 2016
and
2015
, respectively.
The Cleveland Clinic
CBLI has entered into an exclusive license agreement with The Cleveland Clinic pursuant to which CBLI was granted an exclusive license to The Cleveland Clinic’s research base underlying our therapeutic platform and certain product candidates licensed to Panacela. CBLI has the primary responsibility to fund all newly developed patents; however, The Cleveland Clinic retains ownership of those patents covered by the agreement. CBLI also agreed to use commercially diligent efforts to bring one or more products to market as soon as practical, consistent with sound and reasonable business practices and judgments. There were
no
milestone or royalty payments paid to The Cleveland Clinic during the
nine months ended September 30, 2016
or
2015
.
The Company incurred
$0
and
$0
and
$0
and
$9,700
in expense to The Cleveland Clinic related to research grants and agreements for the
three
and
nine months ended September 30, 2016
and
2015
, respectively.
The Company did not have any liabilities to The Cleveland Clinic at
September 30, 2016
or
2015
.
Buffalo BioLabs, LLC
Our CSO, Dr. Andrei Gudkov has business relationships with Buffalo BioLabs, LLC, or BBL, where Dr. Gudkov was a founder and currently serves as its Principal Scientific Advisor. The Company recognized
$178,625
and
$500,979
and
$670,534
and
$917,782
as research and development expense for the
three
and
nine months ended September 30, 2016
and
2015
, respectively. In addition, the Company had
$15,000
and
$0
in accrued expenses payable to BBL and
$0
and
$2,899
in accounts payable to BBL at
September 30, 2016
and
2015
, respectively. We also recognized
$11,553
and
$46,419
from BBL for sublease and other income for the
three months ended September 30, 2016
and
2015
, respectively. Pursuant to our real estate sublease and equipment lease with BBL, we had gross accounts receivables of
$226,023
and
$218,995
and net accounts receivables of
$23,872
and
$0
at
September 30, 2016
and
2015
, respectively.
9. Subsequent event
In October 2016, the Company announced that the DoD has modified its Joint Warfighter Medical Research Program contract with CBLI, valued at up to
$9.2 million
, which supports further development of entolimod as a medical radiation countermeasure.
The modification changes the original statement of work of the contract by eliminating certain tasks no longer deemed critical for the preparation of a Biologics License Application of entolimod as a radiation countermeasure and establishes new tasks to address questions raised by the Food and Drug Administration including an aim to conduct a pharmacokinetic/pharmacodynamic biocomparability study in a nonhuman primate model (the "
Biocomparability Study
") along with other drug manufacturing related activities.
The objective of the Biocomparability Study is to compare the historical drug formulation used in prior pre-clinical and clinical studies versus the to-be-marketed drug product lots of entolimod submitted for approval under CBLI’s application for pre-Emergency Use Authorization. Entolimod is a novel, broad-spectrum investigational drug being developed to mitigate the life-threatening consequences of a radiological attack.
Because this contract modification involves replacement of certain tasks that cost in excess of tasks being eliminated, the aggregate amount of consideration payable to CBLI by the DoD will be unaffected.
|
|
Item 2.
|
Management’s Discussion and Analysis of Financial Condition and Results of Operations
|
This management’s discussion and analysis of financial condition and results of operations and other portions of this quarterly report on Form 10-Q contain forward-looking statements that involve risks and uncertainties. All statements other than statements of current or historical fact contained in this quarterly report, including statements regarding our future financial position, business strategy, new products, budgets, liquidity, cash flows, projected costs, regulatory approvals or the impact of any laws or regulations applicable to us, and plans and objectives of management for future operations, are forward-looking statements. The words “anticipate,” “believe,” “continue,” “should,” “estimate,” “expect,” “intend,” “may,” “plan,” “project,” “will,” and similar expressions, as they relate to us, are intended to identify forward-looking statements. We have based these forward-looking statements on our current expectations about future events. While we believe these expectations
are reasonable, such forward-looking statements are inherently subject to risks and uncertainties, many of which are beyond our control. Our actual future results may differ materially from those discussed here for various reasons. We discuss many of these risks in Item 1A under the heading “Risk Factors” in our Annual Report on Form 10-K for the year ended
December 31, 2015
. Factors that may cause such differences include, but are not limited to, availability and cost of financial resources, results of our research and development efforts and clinical trials, product demand, market acceptance and other factors discussed below and in our other SEC filings, including our Annual Report on Form 10-K for the year ended
December 31, 2015
.
Given these uncertainties, you should not place undue reliance on these forward-looking statements. The forward-looking statements included in this quarterly report are made only as of the date hereof. We do not undertake any obligation to update any such statements or to publicly announce the results of any revisions to any of such statements to reflect future events or developments. This management’s discussion and analysis of financial condition and results of operations should be read in conjunction with our financial statements and the related notes included elsewhere in this filing and with our historical consolidated financial statements and the related notes thereto in our Annual Report on Form 10-K for the year ended
December 31, 2015
.
OVERVIEW
We are an innovative biopharmaceutical company developing novel approaches to activate the immune system and address serious medical needs. Our proprietary platform of Toll-like immune receptor activators has applications in mitigation of radiation injury and immuno-oncology. We combine our proven scientific expertise and our depth of knowledge about our products’ mechanisms of action into a passion for developing drugs to save lives. Our most advanced product candidate is entolimod, an immune-stimulatory agent, which we are developing as a radiation countermeasure and an immunotherapy for oncology and other indications. We conduct business in the U.S. and Russia through several subsidiaries, one of which is wholly-owned, BioLab 612; one of which is owned in collaboration with a financial partner, Panacela; and, a former subsidiary, Incuron. We held a majority ownership interest in Incuron until November 25, 2014, at which time Incuron was deconsolidated, after which we recognized our equitable interest in Incuron’s results of operation as a single line item classified as "Equity in Loss of Incuron, LLC" in our Statements of Operations through April 29, 2015, the date at which our equity interest in Incuron became less than 20%. Subsequent to April 29, 2015, Incuron was accounted for on the cost basis until we sold our remaining equity interest in Incuron on June 30, 2015.
Financial Overview
Our discussion and analysis of our financial condition and results of operations are based on our financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States of America ("
GAAP
"). The preparation of these financial statements requires us to make estimates and judgments that affect our reported amounts of assets, liabilities, revenues and expenses.
On an ongoing basis, we evaluate our estimates and judgments, including those related to accrued expenses, income taxes, stock-based compensation, investments and in-process research and development. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the reported amounts of revenues and expenses that are not readily apparent from other sources. Actual results may differ from these estimates.
Our revenue, operating results and profitability have varied, and we expect that they will continue to vary on a quarterly basis, primarily due to the timing of work completed under new and existing grants, development contracts and collaborative relationships.
Revenue
Our revenue originates from grants and contracts from both United States ("
U.S.
") federal government sources and Russian Federation ("
Russia
") government sources and service contracts with Incuron. U.S. federal grants and contracts are provided to advance research and development of entolimod, our lead product candidate, which we believe is of interest for potential sale to the U.S. Department of Defense ("
DoD
,") or the Biomedical Advanced Research and Development Authority of the U.S. Department of Health and Human Services ("
BARDA
.") Russian government contracts are provided to advance research and development of products that may eventually be licensed for sale in Russia. We provide various research, management, business development and clinical advisory and management services to Incuron.
Research and Development Expenses
Research and development ("
R&D
") costs are expensed as incurred. Advance payments are deferred and expensed as performance occurs. R&D costs include the cost of our personnel (which consists of salaries, incentive and stock-based compensation), out-of-pocket pre-clinical and clinical trial costs usually associated with contract research organizations, drug product manufacturing and formulation, and a pro-rata share of facilities expense and other overhead items.
General and Administrative Expenses
General and administrative ("
G&A
") functions include executive management, finance and administration, government affairs and regulations, corporate development, human resources, legal and compliance. The specific costs include the cost of our personnel consisting of salaries, incentive and stock-based compensation, out-of-pocket costs usually associated with attorneys (both corporate and intellectual property), bankers, accountants and other advisors and a pro-rata share of facilities expense and other overhead items.
Other Income and Expenses
Other recurring income and expenses primarily consists of interest income on our investments, changes in the market value of our derivative financial instruments and foreign currency transaction gains or losses.
Critical Accounting Policies and Significant Estimates
Our critical accounting policies and significant estimates are detailed in our Annual Report on Form 10-K for the year ended December 31,
2015
. Other than as set forth below, our critical accounting policies and significant estimates have not changed substantially from those previously disclosed in our Annual Report on Form 10-K for the year ended December 31,
2015
.
Fair Value of Financial Instruments
We use the Available-For-Sale accounting method to determine the fair value of certain cash equivalents and short-term investments invested in United States Treasury Notes or certificates of deposit. As of
September 30, 2016
, we held approximately
$0.4 million
in cash equivalents,
$9.9 million
in U.S. Treasury Notes which we classified as Level 1 and
$1.0 million
in certificates of deposit which we classified as Level 2.
We use the Black-Scholes model to determine the fair value of certain common stock warrants and stock options not yet issued on a recurring basis, and classify such warrants and options as Level 3 in the fair value hierarchy. The Black-Scholes model utilizes inputs consisting of: (i) the closing price of our common stock; (ii) the expected remaining life; (iii) the expected volatility using a weighted average of historical volatilities of CBLI and a group of comparable companies; and (iv) the risk-free market rate.
As of
September 30, 2016
, we held approximately
$1.3 million
in accrued expenses related to warrants to purchase common stock, which we classified as Level 3.
Three Months Ended
September 30, 2016
Compared to Three Months Ended
September 30, 2015
Revenue
Revenue
increased from
approximately
$0.5 million
for the three months ended
September 30, 2015
to approximately
$1.1 million
three months ended
September 30, 2016
, representing an
increase of
approximately
$0.6 million
, or
127.5%
, principally because of our JWMRP contract awarded to us in September 2015 for continued preclinical development of entolimod's biodefense indication and our grant from the Russian Federation Ministry of Industry and Trade ("
MPT
"), to evaluate safety and tolerability of entolimod as a neo-adjuvant therapy in treatment-naïve patients with primary colorectal cancer. Regarding our other Russian trials funded by MPT, reported contract revenue for the three months ended
September 30, 2016
was approximately equal to the reported contract revenue for the three months ended
September 30, 2015
. Differences in our revenue sources, by program, between the years are set forth in the following table. Prospectively, the DoD contracts will gradually increase in significance and more significantly after the inclusion of a biocomparability study in the scope of the JWMRP contract, required by the FDA as part of the pre-EUA review. Our MPT and Incuron service contracts are scheduled to complete in 2016.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Program
|
|
Three Months Ended September 30,
|
|
|
Funding Source
|
2016
|
|
2015
|
|
Variance
|
DoD
|
JWMRP Contract (1)
|
|
$
|
490,895
|
|
|
$
|
30,745
|
|
|
$
|
460,150
|
|
DoD
|
PRMRP Contract (2)
|
|
8,842
|
|
|
1,748
|
|
|
7,094
|
|
MPT
|
CBLB612 pre-clinical (3)
|
|
—
|
|
|
10,111
|
|
|
(10,111
|
)
|
MPT
|
Entolimod colorectal cancer (3)
|
|
326,014
|
|
|
132,501
|
|
|
193,513
|
|
Incuron
|
Service contract
|
|
184,819
|
|
|
205,389
|
|
|
(20,570
|
)
|
|
|
|
1,010,570
|
|
|
380,494
|
|
|
630,076
|
|
MPT
|
Mobilan pre-clinical (3)
|
|
130,642
|
|
|
121,061
|
|
|
9,581
|
|
|
|
|
$
|
1,141,212
|
|
|
$
|
501,555
|
|
|
$
|
639,657
|
|
|
|
(1)
|
The Congressionally Directed Medical Research Programs (CDMRP) Joint Warfighter Medical Research Program (JWMRP) contract was awarded on September 1, 2015.
|
|
|
(2)
|
The CDMRP Peer Reviewed Medical Research Program (PRMRP) grant was awarded effective as of September 30, 2015.
|
|
|
(3)
|
The grants received from Russian government entities are denominated in Russian Rubles (RUB). The revenue above was calculated using average exchange rates for the periods presented.
|
We anticipate our revenue over the next year will continue to be derived primarily from government grants and contracts. We plan to submit or have submitted proposals for government grants and contracts to various funding sources that have awarded us grants and contracts in the past, but there can be no assurance that we will receive future funding awards. The following table sets forth information regarding our currently active grants and contracts:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
As of September 30, 2016
|
Funding Source
|
|
Program
|
|
Total Award
Value
|
|
Funded Award
Value
|
|
Cumulative
Revenue
|
|
Funded
Backlog
|
|
Unfunded Backlog
|
DoD
|
|
JWMRP Contract
|
|
$
|
9,226,455
|
|
|
$
|
9,226,455
|
|
|
$
|
561,509
|
|
|
$
|
8,664,946
|
|
|
$
|
—
|
|
DoD
|
|
PRMRP Contract
|
|
6,573,992
|
|
|
6,573,992
|
|
|
57,489
|
|
|
6,516,503
|
|
|
—
|
|
MPT
|
|
CBLB612 Pre-clinical (1)
|
|
3,342,247
|
|
|
3,342,247
|
|
|
3,342,247
|
|
|
—
|
|
|
—
|
|
MPT
|
|
Entolimod Colorectal Cancer (1)
|
|
3,035,190
|
|
|
3,035,190
|
|
|
2,763,638
|
|
|
271,552
|
|
|
—
|
|
|
|
|
|
22,177,884
|
|
|
22,177,884
|
|
|
6,724,883
|
|
|
15,453,001
|
|
|
—
|
|
MPT
|
|
Mobilan Pre-clinical (1)
|
|
3,207,186
|
|
|
3,207,186
|
|
|
2,925,785
|
|
|
281,401
|
|
|
—
|
|
|
|
|
|
$
|
25,385,070
|
|
|
$
|
25,385,070
|
|
|
$
|
9,650,668
|
|
|
$
|
15,734,402
|
|
|
$
|
—
|
|
|
|
(1)
|
The grants received from MPT are denominated in Russian Rubles (RUB). Cumulative Revenue includes contract receipts-to-date and outstanding receivables. Backlog amounts are valued at the period end exchange rate. Funded Award Value is the sum of Cumulative Revenue and Funded Backlog. Total Award Value is the sum of Funded Award Value and Unfunded Backlog.
|
Research and Development Expenses
R&D expenses
decreased from
$2.1 million
for the three months ended
September 30, 2015
to
$1.1 million
three months ended
September 30, 2016
, representing a
decrease of
$1.0 million
, or
47.6%
. Variances in individual development programs are noted in the table below. The net decrease is primarily attributable to (i) reduced expenses related to the development of entolimod for biodefense applications as a result of our streamlined focus on the submission of our pre-EUA application and DoD contracts and (ii) the completion of preclinical studies of entolimod for oncology indications in 2015. The remaining variances are not significant and we anticipate an increase in spending for entolimod for biodefense applications as activities increase in connection with the performance of the DoD contracts and our pursuit of approval by the European Medicines Agency.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended September 30,
|
|
|
|
2016
|
|
2015
|
|
Variance
|
Entolimod for Biodefense Applications
|
$
|
606,186
|
|
|
$
|
801,807
|
|
|
$
|
(195,621
|
)
|
CBLB612
|
12,953
|
|
|
40,843
|
|
|
(27,890
|
)
|
Entolimod for Oncology Indications
|
256,592
|
|
|
974,228
|
|
|
(717,636
|
)
|
|
875,731
|
|
|
1,816,878
|
|
|
(941,147
|
)
|
Curaxins
|
137,210
|
|
|
157,083
|
|
|
(19,873
|
)
|
Panacela product candidates
|
91,801
|
|
|
78,606
|
|
|
13,195
|
|
Total research & development expenses
|
$
|
1,104,742
|
|
|
$
|
2,052,567
|
|
|
$
|
(947,825
|
)
|
General and Administrative Expenses
G&A expenses
decreased from
$1.3 million
for the three months ended
September 30, 2015
to
$0.8 million
for the three months ended
September 30, 2016
, representing a decrease of
$0.5 million
, or
40.7%
. These reductions consisted of
$0.4 million
in compensation expense due to reductions in personnel and $0.1 million in other operating expenses.
Other Income and Expenses
Other expense
decreased from
$0.4 million
for the three months ended
September 30, 2015
to
$1.9 million
of
other income
for the three months ended
September 30, 2016
, representing an
income increase
of
$2.3 million
, or
565.1%
. This
increase
was primarily related to a
$1.8 million
non-cash gain related to our warrant liability, and
$0.5 million
was due to reductions in interest expense and foreign currency losses in approximately equal amounts.
Nine Months Ended September 30, 2016
Compared to
Nine Months Ended September 30, 2015
Revenue
Revenue
increased from
approximately
$1.4 million
for the
nine months ended September 30, 2015
to approximately
$2.5 million
for the
nine months ended September 30, 2016
, representing an
increase of
approximately
$1.1 million
, or
75.8%
, principally because of our JWMRP contract awarded to us in September 2015 for continued preclinical development of entolimod's biodefense indication. Regarding our Russian trials funded by MPT, reported contract revenue
increased by
$0.3 million
primarily due to variations in patient enrollment activity. Differences in our revenue sources, by program, between the years are set forth in the following table:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Program
|
|
Nine Months Ended September 30,
|
|
|
Funding Source
|
2016
|
|
2015
|
|
Variance
|
DoD
|
JWMRP Contract (1)
|
|
859,188
|
|
|
30,745
|
|
|
$
|
828,443
|
|
DoD
|
PRMRP Contract (2)
|
|
46,157
|
|
|
1,748
|
|
|
44,409
|
|
MPT
|
CBLB612 pre-clinical (3)
|
|
304,485
|
|
|
73,032
|
|
|
231,453
|
|
MPT
|
Entolimod colorectal cancer (3)
|
|
462,257
|
|
|
358,871
|
|
|
103,386
|
|
Incuron
|
Service contract
|
|
528,411
|
|
|
596,828
|
|
|
(68,417
|
)
|
|
|
|
2,200,498
|
|
|
1,061,224
|
|
|
1,139,274
|
|
MPT
|
Mobilan pre-clinical (3)
|
|
328,239
|
|
|
377,568
|
|
|
(49,329
|
)
|
|
|
|
2,528,737
|
|
|
1,438,792
|
|
|
$
|
1,089,945
|
|
|
|
(1)
|
The Congressionally Directed Medical Research Programs (CDMRP) Joint Warfighter Medical Research Program (JWMRP) contract was awarded on September 1, 2015.
|
|
|
(2)
|
The CDMRP Peer Reviewed Medical Research Program (PRMRP) grant was awarded effective as of September 30, 2015.
|
|
|
(3)
|
The grants received from Russian government entities are denominated in Russian Rubles (RUB). The revenue above was calculated using average exchange rates for the periods presented.
|
Research and Development Expenses
R&D expenses
decreased from
approximately
$5.2 million
for the
nine months ended September 30, 2015
to approximately
$4.3 million
for the
nine months ended September 30, 2016
, representing a
decrease of
approximately
$0.9 million
, or
17.3%
. Variances in individual development programs are noted in the table below. Expenses for CBLB612 increased due to clinical studies in the Russian Federation which completed earlier this year and that were not active in 2015 . These expense increases were offset by reductions in expenses related to our streamlined focus on the submission of our pre-EUA application and for preclinical studies of entolimod for oncology indications and Curaxins. The remaining variances are not significant and we anticipate an increase in spending for entolimod for biodefense applications as activities increase in the performance of the DoD contracts.
|
|
|
|
|
|
|
|
|
|
|
|
Nine Months Ended September 30,
|
|
|
|
2016
|
|
2015
|
|
Variance
|
Entolimod for Biodefense Applications
|
2,174,445
|
|
|
2,615,428
|
|
|
$
|
(440,983
|
)
|
CBLB612
|
456,357
|
|
|
321,273
|
|
|
135,084
|
|
Entolimod for Oncology Indications
|
1,104,788
|
|
|
1,488,644
|
|
|
(383,856
|
)
|
|
3,735,590
|
|
|
4,425,345
|
|
|
(689,755
|
)
|
Curaxins
|
356,518
|
|
|
569,432
|
|
|
(212,914
|
)
|
Panacela product candidates
|
246,041
|
|
|
251,929
|
|
|
(5,888
|
)
|
Total research & development expenses
|
4,338,149
|
|
|
5,246,706
|
|
|
$
|
(908,557
|
)
|
General and Administrative Expenses
G&A expenses
decreased from
$5.2 million
for the
nine months ended September 30, 2015
to
$2.7 million
for the
nine months ended September 30, 2016
, representing a net
decrease of
$2.5 million
, or
47.6%
. These net reductions consisted of a reduction of
$1.0 million
in compensation expense, due to reductions in personnel, a reduction of $1.4 million in professional fees, and offset by an increase of $0.1 million in other operating expenses. The professional fee reduction primarily relates to a one-time expense of $0.6 million related to costs associated with our equity offering in February 2015. The majority of the costs of the February 2015 equity offering were expensed, and not otherwise charged to equity, as the majority of the net proceeds were considered derivative liabilities. Further professional fee reductions of $0.4 million were in connection with non-recurring activities in 2015 associated with strategic transactions and another $0.4 million were in connection with cost savings efforts to streamline operations.
Other Income and Expenses
Other income
increased from
$2.4 million
of
other expense
for the
nine months ended September 30, 2015
to
$3.1 million
of
other income
for the
nine months ended September 30, 2016
, representing an
income increase
of
$5.5 million
, or
229.5%
. This
income increase
was primarily related to a
$4.2 million
variance related to our warrant liability,
$0.4 million
related to our equity in the loss of Incuron accounted for as an equity investment during the
nine months ended September 30, 2016
, and
$0.8 million
in other income primarily due to gains on the sale of equipment and a one-time gain in connection with the settlement of claims associated with our Nota-Bank deposits and foreign currency losses in 2015.
Liquidity and Capital Resources
We have incurred net losses of approximately
$149.5 million
from our inception through
September 30, 2016
. Historically, we have not generated, and do not expect to generate in the immediate future, revenue from sales of product candidates. Since our founding in 2003, we have funded our operations through a variety of means:
|
|
•
|
From inception through
September 30, 2016
, we have raised $144.7 million of net equity capital, including amounts received from the exercise of options and warrants. We have also received $7.3 million in net proceeds from the issuance of long-term debt instruments;
|
|
|
•
|
DoD and BARDA have funded grants and contracts totaling $60.4 million for the development of entolimod for its biodefense indication;
|
|
|
•
|
The Russian Federation has funded a series of our contracts totaling $17.3 million, based on the exchange rates in effect on the date of funding. These contracts include a requirement for us to contribute matching funds, which we have satisfied or expect to satisfy with both the value of developed intellectual property at the time of award, incurred development expenses and future expenses;
|
|
|
•
|
We have been awarded $4.0 million in grants and contracts not described above, all of which have been recognized at
September 30, 2016
;
|
|
|
•
|
Incuron was formed to develop and commercialize the Curaxins product line, including its lead oncology drug candidate CBL0137. In 2015, we sold our ownership interest for approximately $4.0 million and retain a 2% royalty interest in the CBL0137 technology; and
|
|
|
•
|
Panacela was formed to develop and commercialize preclinical compounds, which were transferred to Panacela through assignment and lease agreements. RUSNANO contributed $9.0 million to Panacela and CBLI contributed $3.0 million plus intellectual property to Panacela. As of the date of this filing, CBLI owns 67.57% of Panacela.
|
We have incurred cumulative net losses and expect to incur additional losses related to our R&D activities. We do not have commercial products and have limited capital resources. At
September 30, 2016
, we had cash, cash equivalents and short-term investments of
$14.9 million
which, along with the active government contracts described above, are expected to fund our projected operating requirements beyond one year. However, until we are able to commercialize our product candidates at a level that covers our cash expenses, we will need to raise substantial additional capital, which we may be unable to raise in sufficient amounts, when needed and at acceptable terms. Our plans with regard to these matters may include seeking additional capital through debt or equity financing, the sale or license of drug candidates, or obtaining additional research funding from the U.S. or Russian governments. There can be no assurance that we will be able to obtain future financing on acceptable terms, or that we can obtain additional government financing for our operations. If we are unable to raise adequate capital and/or achieve profitable operations, future operations might need to be scaled back or discontinued. The financial
statements do not include any adjustments relating to the recoverability of the carrying amount of recorded assets and liabilities that might result from the outcome of these uncertainties.
Cash Flows:
The following table provides information regarding our cash flows for the
nine
months ended
September 30, 2016
and
2015
:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
For the Nine Months Ended
September 30,
|
|
2016
|
|
2015
|
|
Variance
|
Cash flows used in operating activities
|
$
|
(5,305,605
|
)
|
|
$
|
(8,859,645
|
)
|
|
$
|
3,554,040
|
|
Cash flows provided by investing activities
|
2,944,754
|
|
|
(12,792,474
|
)
|
|
15,737,228
|
|
Cash flows provided by financing activities
|
539,998
|
|
|
24,809,045
|
|
|
(24,269,047
|
)
|
Effect of exchange rate change on cash and equivalents
|
(45,599
|
)
|
|
101,784
|
|
|
(147,383
|
)
|
Increase in cash and cash equivalents
|
(1,866,452
|
)
|
|
3,258,710
|
|
|
(5,125,162
|
)
|
Cash and cash equivalents at beginning of period
|
5,918,424
|
|
|
3,103,969
|
|
|
2,814,455
|
|
Cash and cash equivalents at end of period
|
$
|
4,051,972
|
|
|
$
|
6,362,679
|
|
|
$
|
(2,310,707
|
)
|
Operating Activities
Net cash used in operating activities decreased by
$3.6 million
to
$5.3 million
for the
nine
months ended
September 30, 2016
from
$8.9 million
for the
nine
months ended
September 30, 2015
. Net cash used in operating activities for the period ending
September 30, 2016
consisted of a reported
net loss
of
$1.4 million
, which was
adjusted down
for
$2.6 million
of net non-cash operating activities, and a
$1.3 million
net decrease
due to changes in operating assets and liabilities. The
$2.6 million
of net non-cash operating activities substantially consisted of changes in the valuation of our warrant liability. Of the net
$1.3 million
of changes in operating assets and liabilities,
$0.9 million
was due to a
net increase
in accounts receivable and other current assets, and
$0.4 million
was due to a
net decrease
in accrued expenses and accounts payable.
Net cash used in operating activities for the
nine
months ended
September 30, 2015
of
$8.9 million
consisted of a reported
net loss
of
$11.4 million
, which was
reduced
for
$2.8 million
of net non-cash operating activities, and a
$0.3 million
net decrease
due to changes in operating assets and liabilities. Of the net non-cash operating activities of
$2.8 million
,
$0.6 million
was due to warrant issuance costs,
$0.4 million
was due to our equity in Incuron, LLC losses, and
$1.8 million
was due to depreciation and other non-cash expenses. The
$1.8 million
of depreciation and other non-cash expenses substantially consisted of a
$1.5 million
change in the valuation of our warrant liability. Of the
net decrease
$0.3 million
in operating assets and liabilities,
$0.1 million
was due to a
net increase
in deferred revenue, and
$0.4 million
was due to a
net increase
in accounts receivable and other currents assets.
Investing Activities
Net cash
provided by
investing activities increased by
$15.7 million
to
$2.9 million
for the
nine
months ended
September 30, 2016
from net cash
used in
investing activities of
$12.8 million
for the
nine
months ended
September 30, 2015
. The net cash
provided by
investing activities for the
nine
months ended
September 30, 2016
consisted primarily of maturities of short-term investments.
Net cash
used in
investing activities for the
nine
months ended
September 30, 2015
consisted primarily of
$16.2 million
of purchases of short-term investments,
$3.0 million
of proceeds received in connection with the sale of Incuron more fully described in Note 4 to the unaudited consolidated condensed financial statements included in this Form 10-Q and
$0.4 million
of cash provided by the release of restricted cash.
Financing Activities
Net cash
provided by
financing activities decreased by
$24.3 million
to
$0.5 million
for the
nine
months ended
September 30, 2016
from
$24.8 million
for the
nine
months ended
September 30, 2015
. Net cash
provided by
financing activities for the
nine
months ended
September 30, 2016
consisted of the sale of
$0.5 million
in Treasury stock.
Net cash
provided by
financing activities for the
nine
months ended
September 30, 2015
of
$24.8 million
consisted of the sale of
$27.3 million
in equity securities offset primarily by
$2.4 million
in principal and interest payments associated with the
repayment of the Hercules Loan more fully described in Note 5, "Debt" included our Annual Report on Form 10-K for the year ended December 31, 2015.
Impact of Exchange Rate Fluctuations
Our reported financial results are affected by changes in foreign currency exchange rates between the U.S. dollar and the Russian ruble. Between January 1,
2016
and
September 30, 2016
, this rate fluctuated by
13.4%
. For calendar
2015
, this rate fluctuated by
29.6%
. Translation gains or losses result primarily from the impact of exchange rate fluctuations on the reported U.S. dollar equivalent of ruble denominated cash and cash equivalents, restricted cash and short-term investments. Variances in the exchange rate for these items have not been realized; as such the resulting gains or losses are recorded as other comprehensive income in the equity section of the balance sheet.
Off-Balance Sheet Arrangements
We have not entered into any off-balance sheet arrangements.
|
|
Item 3.
|
Quantitative and Qualitative Disclosures About Market Risk
|
Not required for smaller reporting company filers.
|
|
Item 4.
|
Controls and Procedures
|
Effectiveness of Disclosure
Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, evaluated the effectiveness of our disclosure controls and procedures as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended, or the Exchange Act, as of
September 30, 2016
. Our management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Based on the evaluation of our disclosure controls and procedures as of
September 30, 2016
, our Chief Executive Officer and Chief Financial Officer concluded that, as of such date, our disclosure controls and procedures were effective to ensure that information required to be disclosed by us in reports that we file or submit under the Exchange Act is (1) recorded, processed, summarized and reported within the periods specified in the SEC’s rules and forms, and (2) accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure.
Changes in Internal Control over Financial Reporting
There was no change in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15(d)-15(f) under the Exchange Act) during the fiscal quarter ended
September 30, 2016
, that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.
PART II – Other Information